MyKronoz Unveils Its New Flagship ZeBuds Collection, With 3 Models of Stylish and Affordable True Wireless Stereo Earphones
Swiss wearable maker MyKronoz today announces three models of fashionable, affordable and full-featured true wireless earphones: ZeBuds Lite, Premium and Pro.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005622/en/
ZeBuds Collection (Photo: MyKronoz)
ZeBuds first generation was introduced to the market earlier this year and has already received high marks.
While sharing identical earbud design, the same set of advanced functions and specs, the new and enlarged ZeBuds lineup comes with 3 sub collections: Lite, Premium and Pro, each featuring 6 colors of earphones and matching USB-C charging case. Each line presents a unique aspect:
- ZeBuds Lite: true wireless earbuds with a matt charging case boasting the familiar look of a sleek lighter. MSRP of 59,90€/$ only. Available September 2019.
- ZeBuds Premium: having the same size and shape as ZeBuds lite, the Premium features an elegant aluminum charging case. MSRP of 79,90€/$ only. Available October 2019.
- ZeBuds Pro: glass-finished and Qi-certified wireless charging case whose shape has been greatly inspired by Swiss traditional pocket-watch. MSRP of 99,90€/$. Available November 2019.
Taking into account the feedbacks of MyKronoz community the all-new ZeBuds boast an extended playtime of up to 16 hours, work with MyKronoz app, where users will be able to control the settings of their earbuds, including an equalizer function to get the best sound, and support OTA firmware upgrade.
A Qi-wireless charging case is also now available for a convenient charging experience (ZeBuds Pro only).
The 3 models come with a reliable Bluetooth 5.0 connectivity to manage music, calls and voice commands remotely.
“ZeBuds is the perfect combination of superior Swiss design, sound and function - at an accessible price.” said Boris Brault, founder and CEO of MyKronoz “Staying fully committed to our mission of making wearable for everyone, we have developed three models of ZeBuds with a similar set of core features but distinctive design material and adds-on to ensure we can cater a large audience and perfectly fit into their everyday lives. People should be able to make calls, voice commands, listen to their favorite music or podcasts, without having to choose between style and performance - we have therefore reunited the best of both worlds with ZeBuds collection.”
Compatible with both iOS and Android, offering a beautiful design and lightweight charging case, supreme sound, extended battery life, touch controls and voice command capabilities - ZeBuds were designed for people who want to experience true wireless freedom with no compromise on style.
Building on its strong background in wearable technology, MyKronoz seizes additional opportunities in the flourishing market of wireless earbuds. The expansion of ZeBuds range appears as a strategic move for the company to leverage expertise in developing affordable consumer-driven products and diversify to offer a full ecosystem.
In addition to ZeBuds, MyKronoz offers a complete line of affordable fashion wearables, starting at 29.90 €/$, featuring activity tracker, smartwatches, sport smartwatches and hybrids to cater a large and diversified audience.
- ZeTrack - a slim and full-featured HR activity tracker with color touchscreen. MSRP: 29.90€/$.
- ZeNeo - a real powerful smartwatch with mic & speaker that looks like a sleek activity tracker. MSRP: 59.90€/$.
- ZeRound3 Lite - the go-to smartwatch designed for your active lifestyle. MSRP: 79.90€/$.
- ZeRound3 - the genuinely stylish connected smartwatch with AMOLED display. MSRP: 99.90€/$.
MyKronoz will pursue an innovate path with the coming launch of ZePop - the hybrid smartwatch that blends fashion and tech. MSRP: 129,90€/$ as well as ZeTime2 - a stainless steel hybrid smartwatch with microphone, AMOLED display and real mechanical hands. MSRP: 199,90€/$.
MyKronoz is part of BOW Group, a global player in lifestyle consumer products, operating worldwide in the design and wearables markets with its 2 brands: MyKronoz and LEXON.
Since July 2015, BOW has opened up its capital to Next Stage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International. MyKronoz ZeTime has convinced over 40,000 backers in more than 100 countries and became the world's highest funded hybrid smartwatch with more than $8 million raised, as well as the largest crowdfunding campaign ever from a European company and the most backed product of 2017 on Kickstarter.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
Annabel Corlay, email@example.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met
RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 16:30:00 EEST | Press release
On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 15:00:00 EEST | Press release
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past
Visa B2B Connect Expands to 32 New Countries and Announces Integration With Infosys20.9.2019 14:00:00 EEST | Press release
Visa Inc. (NYSE:V) today announced that its Visa B2B Connect network has doubled its reach – from 30 global trade corridors at launch in June 2019, to 62, with the goal to expand to over 100 countries in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005082/en/ Visa B2B Connect (Graphic: Business Wire) In addition, Infosys, a global leader in next-generation digital services and consulting, is integrating with the Visa B2B Connect network to bring Visa B2B Connect platform access to their participating financial institutions worldwide. Through this new connection, participating financial institutions worldwide can take advantage of the ability to quickly and securely process corporate cross-border payments globally through Visa B2B Connect.1 “Visa B2B Connect is a fast, secure and more efficient network, designed specifically to overcome obstacles in the cross-border corporate payments space,” said Alan Koenigsbe
Open Day at ISAE-SUPAERO!20.9.2019 12:53:00 EEST | Press release
As part of the Science Festival, this year organized on the theme of “Talking about Science, Imagining the Future”, ISAE-SUPAERO will open up its entire campus to the public on Saturday, October 12th from 10 am to 6 pm. Intended for families, companies, partners, journalists and alumni, this event should bring in over 3,000 attendees, as was the case in the three previous years! The program for the day includes many opportunities to discover science today and our vision of the science of the future, with the challenges this entails for the future of our planet. On the program: ➢ Visits to the laboratories and research departments with flight simulators ➢ Visit to the aeroacoustic wind tunnel, unique in Europe, ➢ Demonstrations: how to fly an airplane, Enoskelet, augmented humans, aeroelasticity, drones, use of the gyroscopic effect in space systems, piezoelectric effect, lasers for communicating at the speed of light on Earth and in space, the infinitely small in 3D, Robot Firefighter
William Priest to Step Down as CEO in 2020, Will Remain at Firm as Executive Chairman and Co-CIO20.9.2019 10:00:00 EEST | Press release
Epoch Investment Partners, Inc., announced that William Priest will step down as the firm's CEO effective April 1, 2020. He will become Epoch's Executive Chairman and will continue to lead the investment team and serve as co-CIO. He will also retain his portfolio management responsibilities, including his lead portfolio manager role with Epoch's Global Choice and Global Absolute Return strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005076/en/ Philipp Hensler (Photo: Business Wire) Philipp Hensler, Epoch's President and COO, will become the firm's CEO. Hensler brings to the role extensive leadership experience at asset management firms globally. His earlier background as a portfolio manager has imbued him with an investment-oriented perspective that aligns with Epoch's investment-centric culture. “Investing remains my lifelong passion," said Priest, who helped found Epoch in 2004. “Best practice suggests a s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom